Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12400974rdf:typepubmed:Citationlld:pubmed
pubmed-article:12400974lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12400974lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:12400974lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:12400974lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:12400974pubmed:issue4lld:pubmed
pubmed-article:12400974pubmed:dateCreated2002-10-28lld:pubmed
pubmed-article:12400974pubmed:abstractTextTo determine the efficacy and safety of the FOLFOX 2 regimen in patients with pretreated advanced colorectal cancer.lld:pubmed
pubmed-article:12400974pubmed:languageenglld:pubmed
pubmed-article:12400974pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12400974pubmed:citationSubsetIMlld:pubmed
pubmed-article:12400974pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12400974pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12400974pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12400974pubmed:statusMEDLINElld:pubmed
pubmed-article:12400974pubmed:issn0300-8916lld:pubmed
pubmed-article:12400974pubmed:authorpubmed-author:BertoliniFede...lld:pubmed
pubmed-article:12400974pubmed:authorpubmed-author:LuppiGabriele...lld:pubmed
pubmed-article:12400974pubmed:authorpubmed-author:ZanelliFrance...lld:pubmed
pubmed-article:12400974pubmed:authorpubmed-author:Di...lld:pubmed
pubmed-article:12400974pubmed:authorpubmed-author:PifferiMicolMlld:pubmed
pubmed-article:12400974pubmed:issnTypePrintlld:pubmed
pubmed-article:12400974pubmed:volume88lld:pubmed
pubmed-article:12400974pubmed:ownerNLMlld:pubmed
pubmed-article:12400974pubmed:authorsCompleteYlld:pubmed
pubmed-article:12400974pubmed:pagination270-2lld:pubmed
pubmed-article:12400974pubmed:dateRevised2008-12-12lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:meshHeadingpubmed-meshheading:12400974...lld:pubmed
pubmed-article:12400974pubmed:articleTitleFolfox 2 regimen in heavily pretreated patients with advanced colorectal cancer.lld:pubmed
pubmed-article:12400974pubmed:affiliationDepartment of Oncology and Hematology, Policlinico, Modena, Italy. luppi.g@policlinico.mo.itlld:pubmed
pubmed-article:12400974pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12400974pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12400974pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed